15, and 43% below where it was two weeks ago. The daily average of hospitalizations stands at 46,447, the lowest level since Nov. 14 peak of 806,795, according to a New York Times Tracker. The seven-day average of new cases totaled 54,734 on Wednesday, the lowest level seen since late-July, down 56% from two weeks ago and 93% below its Jan. continues to improve, as daily new case counts and hospitalizations continue their downward slide, and as the death toll holds below the 2,000-per-day mark. The move comes as the outlook for COVID-19 in the U.S.
"These are typically people who have not received a COVID-19 vaccination, older people, people with immunodeficiencies and people living with chronic diseases."
"Molnupiravir should be provided only to non-severe COVID-19 patients with the highest risk of hospitalization," the WHO said in a statement. It's the first oral antirival to be added to the agency's guidelines, but with little safety data available yet, the WHO is advising close monitoring. The World Health Organization said Thursday it is updating its guidelines on COVID-19 treatments to include molnupiravir, the antiviral developed by Merck & Co. The stock has tumbled 18.8% over the past three months through Wednesday, while the S&P 500 undefined has slipped 3.4%.Ĭoronavirus tally: WHO adds Merck's antiviral to its treatment guidelines for non-severe patients The FactSet EPS consensus is $1.44 and the sales consensus of $1.51 billion implies a 7.3% decline. "However, as we have moved into 2022, we have seen these factors abate, and sales are regaining traction." For the first quarter, the company expects EPS of $1.10 to $1.20 and a "low double-digit" percentage decline in sales. "January was a tough month as inclement weather and the Omicron spike caused a slowdown in our business, further impacted by inventory delays in key areas," said Chief Executive Bruce Thorn. Gross margin declined to 37.3% from 39.4%. Sales slipped 0.3% to $1.73 billion, topping the FactSet consensus of $1.72 billion, as same-store sales fell 2.3% to beat expectations of a 3.1% decline. Excluding nonrecurring items, adjusted earnings per share of $1.75 was below the FactSet consensus of $1.89. 29 fell to $49.8 million, or $1.63 a share, from $98.0 million, or $2.59 a share, in the year-ago period. undefined were indicated down less than 1% in premarket trading Thursday, after the discount retailer reported fiscal fourth-quarter profit and that missed expectations while sales topped, citing a "tough" month of January, and provided a downbeat outlook for the current quarter. Big Lots misses profit expectations but sales top forecasts after a 'tough' January
0 kommentar(er)
